HCAT

In Q1 2026, Health Catalyst reported revenues of $70.76 million, exceeding estimates by 2.3% despite a 10.9% year-over-year decline, leading to an 11.1% stock jump, though full-year guidance missed expectations. The company signed an agreement on June 4, 2026, to sell its Vitalware business for $147 million in cash, closing on July 31, 2026, to focus on core technology and AI, using proceeds to repay credit facility debt. For Q2 2026, revenue was $70.5 million, down 13% year-over-year but exceeding guidance, and adjusted EBITDA increased by 6% to $9.9 million, yet the stock declined by 25.1% after the announcement. In September 2026, Simeon Kohl was appointed CEO and President, and Tami Reller joined the board. On September 14, 2026, CEO Simeon Kohl purchased 59,000 shares of common stock. On September 17, 2026, analysts trimmed price targets due to perceived churn, down-sell risks, potential divestiture questions, and caution during the company's transformation. Overall, Health Catalyst's stock performance has declined over various timeframes, including a 39.93% decrease over the last 12 months and a -27.62% year-to-date return as of September 16, 2026.